Cemdisiran, terminal sugar modification-
Cemdisiran is an investigational GalNAc-conjugated siRNA therapeutic designed to silence C5 mRNA and inhibit complement component C5 production in the liver. Its application is primarily in research for complement-mediated diseases, with studies demonstrating C5 suppression in both in vitro systems and in vivo preclinical models.
Product Specifications
CAS Number
1436858-07-9
Smiles
CC (=O) N[C@@H]1[C@@H] (O) [C@@H] (O) [C@@H] (CO) O[C@H]1OCCCCC (=O) NCCCNC (=O) CCOCC (COCCC (=O) NCCCNC (=O) CCCCO[C@@H]1O[C@H] (CO) [C@H] (O) [C@H] (O) [C@H]1NC (C) =O) (COCCC (=O) NCCCNC (=O) CCCCO[C@@H]1O[C@H] (CO) [C@H] (O) [C@H] (O) [C@H]1NC (C) =O) NC (=O) CCCCCCCCCCC (=O) N1C[C@H] (O) C[C@H]1COP (O) (O) =O
Molecular Formula
C78H140N11O34P
Molecular Weight
1806.97
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog